LOGIN  |  REGISTER
Viking Therapeutics
Cue Biopharma

Globus Medical Announces Launch of the MARVEL™ Growing Rod System, the company’s first product designed specifically for early onset scoliosis

July 31, 2023 | Last Trade: US$81.78 1.64 -1.97

AUDUBON, Pa., July 31, 2023 (GLOBE NEWSWIRE) -- Globus Medical, Inc. (NYSE: GMED), a leading musculoskeletal solutions company, today announced the commercial launch of the MARVEL™ Growing Rod System, which is designed for pediatric patients with early onset scoliosis to obtain and maintain correction while allowing for growth through minimally invasive distraction.

MARVEL™ growing rods feature a powerful geared mechanism that provides reliable, efficient lengthening through a large 40mm or 60mm expansion range, with PEEK polymer bearing surfaces to minimize wear. Lengthening of each rod is achieved through a minimally invasive procedure with a small incision for driver access to minimize soft tissue disruption.

“The need to balance curve correction with growth in patients with early onset scoliosis makes it one of the most challenging conditions facing pediatric spine surgeons,” says Dr. Shyam Kishan, board-certified orthopedic surgeon and Medical Director at Medical City Children’s Hospital Orthopedics & Spine in Dallas, TX. “MARVEL™’s novel design allows for reliable distraction for continued spinal growth while minimizing impact to the patient.”

“Globus Medical is committed to providing world class solutions for the most complex spinal disorders,” said David Hole, President, Spine at Globus Medical. “MARVEL™, together with our recent launch of the REFLECT™ Scoliosis Correction System, a non-fusion growth modulation system for treatment of skeletally immature idiopathic scoliosis patients, demonstrates our commitment to leveraging our product development engine to serve children with scoliosis and the surgeons who care for them. We are very excited to bring these innovations to the marketplace.”

To learn more, visit GlobusMedical.com/products/MARVEL.  

Indications

MARVEL™ Growing Rods are indicated in patients under 10 years of age with potential for additional spine growth who require surgical treatment to obtain and maintain correction of severe, progressive, life threatening, early onset spinal deformities associated with thoracic insufficiency, including early onset scoliosis, as part of a growing rod construct.

About Globus Medical, Inc. 

Globus Medical, Inc. is a leading musculoskeletal solutions company based in Audubon, PA. The company was founded in 2003 by an experienced team of professionals with a shared vision to create products that enable surgeons to promote healing in patients with musculoskeletal disorders. Additional information can be accessed at http://www.globusmedical.com

Safe Harbor Statements 

All statements included in this press release other than statements of historical fact are forward-looking statements and may be identified by their use of words such as “believe,” “may,” “might,” “could,” “will,” “aim,” “estimate,” “continue,” “anticipate,” “intend,” “expect,” “plan” and other similar terms. These forward-looking statements are based on our current assumptions, expectations and estimates of future events and trends. Forward-looking statements are only predictions and are subject to many risks, uncertainties and other factors that may affect our businesses and operations and could cause actual results to differ materially from those predicted. These risks and uncertainties include, but are not limited to, health epidemics, pandemics and similar outbreaks, including the COVID-19 pandemic, factors affecting our quarterly results, our ability to manage our growth, our ability to sustain our profitability, demand for our products, our ability to compete successfully (including without limitation our ability to convince surgeons to use our products and our ability to attract and retain sales and other personnel), our ability to rapidly develop and introduce new products, our ability to develop and execute on successful business strategies, our ability to comply with laws and regulations that are or may become applicable to our businesses, our ability to safeguard our intellectual property, our success in defending legal proceedings brought against us, trends in the medical device industry, general economic conditions, and other risks. For a discussion of these and other risks, uncertainties and other factors that could affect our results, you should refer to the disclosure contained in our most recent annual report on Form 10-K filed with the Securities and Exchange Commission, including the sections labeled “Risk Factors” and “Cautionary Note Concerning Forward-Looking Statements,” and in our Forms 10-Q, Forms 8-K and other filings with the Securities and Exchange Commission. These documents are available at www.sec.gov. Moreover, we operate in an evolving environment. New risk factors and uncertainties emerge from time to time and it is not possible for us to predict all risk factors and uncertainties, nor can we assess the impact of all factors on our business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in any forward-looking statements. Given these risks and uncertainties, readers are cautioned not to place undue reliance on any forward-looking statements. Forward-looking statements contained in this press release speak only as of the date of this press release. We undertake no obligation to update any forward-looking statements as a result of new information, events or circumstances or other factors arising or coming to our attention after the date hereof.  

Contact: 
Brian Kearns 
Senior Vice President, Business Development and Investor Relations
Phone: (610) 930-1800 
Email: This email address is being protected from spambots. You need JavaScript enabled to view it. 
www.globusmedical.com

Astria Therapeutics

Stock Quote

Featured Stock

Immix Biopharma

Immix Biopharma is a clinical-stage biopharmaceutical company pioneering a novel class of CAR-T cell therapies and Tissue-Specific Therapeutics targeting oncology and immuno-dysregulated diseases with >75 patients treated to-date. Our lead cell therapy asset is NXC-201...

CLICK TO LEARN MORE

Featured Stock

Compass Therapeutics

Compass Therapeutics is a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases. The company's scientific focus is on the relationship between angiogenesis, the immune system, and tumor growth...

CLICK TO LEARN MORE

End of content

No more pages to load

Next page

COPYRIGHT ©2023 HEALTH STOCKS HUB